Published in Gene Therapy Weekly, December 8th, 2005
Net loss for the third quarter was $10.1 million, compared to a net loss of $8.9 million for the same period in 2004. At September 30, 2005, XenoPort had cash and cash equivalents and short-term investments of $78.8 million.
Since the beginning of the third quarter, XenoPort has announced the following progress in its clinical-stage development programs:
- A phase IIb clinical trial demonstrated that XP13512 provided...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.